Britannia Life Sciences Inc.
Britannia Life Sciences Inc. (BLAB.CN) PE Ratio — Current & Historical Data
Trailing twelve months (TTM) P/E, forward P/E, PEG, and annual PE history — from market prices and filings.
blab.cn · pe ratio · data through Jun 10, 2026
Core PE Ratio Metrics
Trailing 12 months · TTMInsufficient PE history data (fewer than 3 valid fiscal years).
PE Ratio vs Peers
Biotechnology · 5 peers · Annual PE| Company | Market Cap | PE (Annual) | vs Avg | EPS (TTM) |
|---|---|---|---|---|
Britannia Life Sciences Inc.You BLAB.CN | $14M | 0.67x | — | $0.13 |
 Rapid Dose Therapeutics Corp. DOSE.CN | $12M | N/A | — | -$0.04 |
 Hemostemix Inc. HEM.V | $11M | N/A | — | -$0.03 |
 Pharmala Biotech Holdings Inc. MDMA.CN | $15M | N/A | — | -$0.02 |
 Marvel Biosciences Corp. MRVL.V | $13M | N/A | — | -$0.05 |
 Pangenomic Health Inc. NARA.CN | $5M | N/A | — | -$0.19 |
* N/A — Company is not profitable (TTM) · excluded from industry average · ▸ FMP /stock-peers + /ratios?limit=1 · priceToEarningsRatio
About PE Ratio & Methodology
The price-to-earnings (P/E) ratio for Britannia Life Sciences Inc. (BLAB.CN) measures how much investors pay for each dollar of the company's trailing earnings. BLAB.CN's current PE ratio of 0.67x is calculated by dividing its stock price of $0.09 by its TTM earnings per share of $0.13.
Frequently asked questions
BLAB.CN pe ratio · 6 questionsBLAB.CN's current PE ratio is 0.67x as of 2026-06-10, based on a stock price of $0.09 and TTM EPS of $0.13. Data sourced from Financial Modeling Prep via BLAB.CN's SEC 10-K and 10-Q filings.
▸ Source: FMP · /ratios-ttm · /ratios annual · /analyst-estimates · /stock-peers · Britannia Life Sciences Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: 2026-06-10